The Hidden Benefits of Septal Myectomy
Authors:
Open Access
- 12 December 2023
- journal article
- editorial
- Published by Elsevier in JACC: Advances
- Vol. 3 (1) , 100762
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction TherapyJACC, 2022
- The sham effect of invasive interventions in chronic coronary syndromes: a systematic review and meta-analysisBMC Cardiovascular Disorders, 2022
- Association of Septal Myectomy With Quality of Life in Patients With Left Ventricular Outflow Tract Obstruction From Hypertrophic CardiomyopathyJAMA Network Open, 2022
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2021
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2020
- Health-Related Quality of Life Outcomes in PARADIGM-HFCirculation: Heart Failure, 2017